Interferons return for treatment of chronic hepatitis B

Affiliations

Comment

Gary L Davis. Rev Gastroenterol Disord. 2005 Summer.

. 2005 Summer;5(3):178-81.

¹ Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, Texas, USA.

No abstract available

Comment on

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Marcellin P, et al. N Engl J Med. 2004 Sep 16;351(12):1206-17. doi: 10.1056/NEJMoa040431. N Engl J Med. 2004. PMID: 15371578 Clinical Trial.
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Liaw YF, et al. N Engl J Med. 2004 Oct 7;351(15):1521-31. doi: 10.1056/NEJMoa033364. N Engl J Med. 2004. PMID: 15470215 Clinical Trial.